NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $5.56 -0.04 (-0.63%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vir Biotechnology Stock (NASDAQ:VIR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$5.52▼$5.6750-Day Range$4.28▼$5.7352-Week Range$4.16▼$14.45Volume271,997 shsAverage Volume1.54 million shsMarket Capitalization$771.70 millionP/E RatioN/ADividend YieldN/APrice Target$17.30Consensus RatingModerate Buy Company Overview Vir Biotechnology, Inc. is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents. The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis. Vir entered into a notable collaboration with GlaxoSmithKline to develop monoclonal antibody therapies against SARS-CoV-2. Beyond its lead COVID-19 antibody program, Vir’s research focuses on next‐generation antiviral treatments and vaccines, employing deep sequencing and single-cell analysis to accelerate discovery. Preclinical and clinical trials are underway across multiple indications, reflecting the company’s commitment to addressing unmet medical needs in infectious diseases. Founded in 2017, Vir Biotechnology is headquartered in San Francisco, California, and operates research and development facilities in the United States and Europe. The company’s management team comprises experienced leaders in biotechnology and infectious disease research, driving strategic partnerships with academic institutions and global health organizations. Through its integrated platform and collaborative model, Vir aims to rapidly translate scientific insights into therapies that can improve outcomes for patients worldwide.AI Generated. May Contain Errors. Read More Vir Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreVIR MarketRank™: Vir Biotechnology scored higher than 74% of companies evaluated by MarketBeat, and ranked 288th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVir Biotechnology has a consensus price target of $17.30, representing about 211.4% upside from its current price of $5.56.Amount of Analyst CoverageVir Biotechnology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.10% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Vir Biotechnology has recently decreased by 0.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.10% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Vir Biotechnology has recently decreased by 0.59%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.83 News SentimentVir Biotechnology has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 21 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $404,830.00 in company stock.Percentage Held by Insiders16.00% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIR Stock News HeadlinesVir Biotechnology (NASDAQ:VIR) Director Sells $128,480.00 in StockOctober 3, 2025 | insidertrades.comLifesaving new antibody blocks 98.5% of all known HIV strains3 hours ago | msn.comURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.October 7 at 2:00 AM | StockEarnings (Ad)Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 20253 hours ago | finance.yahoo.comVir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 16, 2025 | seekingalpha.comEvercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationSeptember 3, 2025 | msn.comThe Play On Vir BiotechnologySeptember 3, 2025 | seekingalpha.comVir Biotechnology initiated with an Outperform at Evercore ISISeptember 3, 2025 | msn.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $7.34 at the start of the year. Since then, VIR shares have decreased by 24.3% and is now trading at $5.5550. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) announced its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.08. The business's revenue was down 60.5% on a year-over-year basis. Read the conference call transcript. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V). Company Calendar Last Earnings8/06/2025Today10/07/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VIR CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees580Year Founded2016Price Target and Rating Average Price Target for Vir Biotechnology$17.30 High Price Target$31.00 Low Price Target$12.00 Potential Upside/Downside+209.5%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$521.96 million Net Margins-2,895.94% Pretax Margin-2,894.48% Return on Equity-50.22% Return on Assets-40.78% Debt Debt-to-Equity RatioN/A Current Ratio7.01 Quick Ratio7.01 Sales & Book Value Annual Sales$74.21 million Price / Sales10.46 Cash FlowN/A Price / Cash FlowN/A Book Value$8.35 per share Price / Book0.67Miscellaneous Outstanding Shares138,920,000Free Float116,689,000Market Cap$776.56 million OptionableOptionable Beta1.27 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VIR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.